Primary information |
---|
sequence ID | Seq_8193 |
Peptide sequence | TGKEKVTSGSTTTT |
CancerPDF_ID | CancerPDF_ID1235, CancerPDF_ID9671, CancerPDF_ID12417, |
PMID | 21136997,21533267,26992070 |
Protein Name | Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain |
UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
Fluid | Serum,Serum,Serum |
M/Z | 1396.70455,699.35,1396.7046 |
Charge | 1,2,NA |
Mass (in Da) | NA,NA,1397.715885 |
fdr | NA,NA,NA |
Profiling Technique | LC-MS,LC-MS,LC-MS |
Peptide Identification technique | LC-MS-MS/MS,LC/MS/MS,LC-MS/MS |
Quantification Technique | LC-ESI-MS,Multiple Reaction Monitoring,NA |
Labelled/Label Free | Label Free,Label Free,Label Free |
FDR | NA,1.49,FDR 1 % |
CancerPDF_ID | CancerPDF_ID1235, CancerPDF_ID9671, CancerPDF_ID12417, |
p-Value | NA,NA,NA |
Software | MASCOT(v. 2.2.01),MASCOT,SEQUEST and Maxquant |
Length | 14,14,14 |
Cancer Type | Colorectal cancer,Lung adenocarcinoma,Melanoma |
Database | SwissProt Database,Swissprot Database (57.4),SwissProt Database |
Modification | NA,NA,NA |
Number of Patients | 30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples |
Regulation | NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." |
Validation | Leave One out Cross validation,MRM-based validation of 19 candidates,na |
Sensitivity | NA,NA,NA |
Specificity | NA,NA,NA |
Accuracy | NA,NA,NA |
Peptide Atlas | NA |
IEDB | |